James Doolin, MD
Hematology · Boston, MANPI 1679923817
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Galvanize Therapeutics, Inc at 43.6% of the total. 2025 is the largest year on record at $436, more than ten times the $17 reported in 2021. That places this record below the midpoint for hematology clinicians in MA, where the typical reported total is $3,500.
Across 10 payments — averaging $47.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galvanize Therapeutics, Inc$205
- Johnson & Johnson$113
- Takeda Pharmaceuticals U.S.A., Inc.$40
- Tempus AI, Inc$32
- Astellas Pharma US Inc$23
- Array Biopharma Inc$23
- plus $34 from 2 others
What the payments were for
- Food & beverage$471100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galvanize Therapeutics, Inc | 1 | $205 |
| Johnson & Johnson | 3 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Tempus AI, Inc | 1 | $32 |
| Astellas Pharma US Inc | 1 | $23 |
| Array Biopharma Inc | 1 | $23 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$205
How this compares
$471 in reported general payments places this provider in the 40th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 65 | $733,078 |
| LenvimaLenvatinib Mesylate | 23 | $569,743 |
| OrgovyxRelugolix | 34 | $89,481 |
| Abiraterone Acetate | 30 | $76,891 |
| EliquisApixaban | 37 | $22,898 |
| CreonLipase/Protease/Amylase | 13 | $15,149 |
| Oxycodone Hcl | 117 | $2,647 |
| Tamsulosin Hcl | 35 | $909 |
| Dexamethasone | 51 | $740 |
| Prochlorperazine Maleate | 47 | $512 |
| Gabapentin | 34 | $309 |
| Olanzapine | 23 | $298 |
| Ondansetron Hcl | 30 | $264 |
| Pantoprazole Sodium | 17 | $259 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $258 |
Paid to pharmacies, not to this prescriber.
Other hematology in Boston
- Edward BenzBoston$747K
- David KuterBoston$543K
- Jacalyn RosenblattBoston$455K
- Lynn BryBoston$286K
- John SloanBoston$257K
- Andrew EvensBoston$217K
- Omar NadeemBoston$191K
- Nathan ConnellBoston$145K
- Jean ConnorsBoston$144K
- Heather BenjaminBoston$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.